3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
21
Thoracic
3
Sarcoma
2
NET
2
Lymphoid
2
Head & Neck
2
Endocrine
2
Dermatologic
2
Breast
2
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Lymphoma
369
Lymphoma, Non-Hodgkin
346
Leukemia, Lymphocytic, Chronic, B-Cell
321
Precursor Cell Lymphoblastic Leukemia-Lymphoma
291
Lymphoma, Large B-Cell, Diffuse
244
Lymphoma, Follicular
236
Leukemia
197
Hodgkin Disease
170
Lymphoma, Mantle-Cell
164
Leukemia, Myeloid, Acute
160
Multiple Myeloma
134
Myelodysplastic Syndromes
130
Recurrence
125
Burkitt Lymphoma
123
Lymphoma, B-Cell, Marginal Zone
120
Lymphoma, T-Cell, Cutaneous
92
Mycosis Fungoides
82
Neoplasms
81
Lymphoma, B-Cell
81
Waldenstrom Macroglobulinemia
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
70
Sezary Syndrome
67
Lymphoma, Large-Cell, Immunoblastic
65
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
57
Lymphoma, Large-Cell, Anaplastic
54
Neoplasms, Plasma Cell
52
Myeloproliferative Disorders
52
Primary Myelofibrosis
46
Hematologic Neoplasms
44
Blast Crisis
43
Interventions
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Digestive System Neoplasms
×
Lymphoid
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts
NCT02602067
2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1
Terminated
2 enrolled